N4 Pharma (N4P) Competitors GBX 0.50 +0.05 (+11.11%) As of 08/22/2025 11:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock N4P vs. HELD, HLN, BXP, HIK, HCM, INDV, AMYT, AGY, APH, and ANCRShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), and Animalcare Group (ANCR). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Its Competitors Hellenic Dynamics Haleon Beximco Pharmaceuticals Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Animalcare Group Hellenic Dynamics (LON:HELD) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Does the media refer more to HELD or N4P? In the previous week, Hellenic Dynamics' average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score. Company Overall Sentiment Hellenic Dynamics Neutral N4 Pharma Neutral Which has higher earnings & valuation, HELD or N4P? N4 Pharma has higher revenue and earnings than Hellenic Dynamics. N4 Pharma is trading at a lower price-to-earnings ratio than Hellenic Dynamics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHellenic DynamicsN/AN/A-£5.22M-£3.550.00N4 Pharma£8.84K243.55-£1.63M-£0.35-1.44 Do insiders and institutionals hold more shares of HELD or N4P? 0.1% of Hellenic Dynamics shares are held by institutional investors. 72.9% of Hellenic Dynamics shares are held by company insiders. Comparatively, 18.0% of N4 Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is HELD or N4P more profitable? Hellenic Dynamics has a net margin of 0.00% compared to N4 Pharma's net margin of -18,399.86%. N4 Pharma's return on equity of -90.68% beat Hellenic Dynamics' return on equity.Company Net Margins Return on Equity Return on Assets Hellenic DynamicsN/A -364.21% N/A N4 Pharma -18,399.86%-90.68%-56.00% SummaryHellenic Dynamics beats N4 Pharma on 5 of the 9 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£2.15M£2.26B£5.75B£3.22BDividend Yield3.12%2.92%4.40%5.04%P/E Ratio-1.444.3631.30164.70Price / Sales243.55691.66432.98310,111.42Price / Cash2.2510.3737.7327.93Price / Book1.1211.959.535.91Net Income-£1.63M£20.70B£3.26B£5.89B7 Day Performance19.62%1.13%2.13%49.52%1 Month Performance39.66%4.38%2.80%56.36%1 Year Performance-9.26%3.69%30.68%136.20% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.50+11.1%N/A-16.7%£2.15M£8.84K-1.445Gap DownHELDHellenic DynamicsN/AGBX 0.01flatN/AN/A£14KN/A0.00N/AHLNHaleon0.9339 of 5 starsGBX 356.40-0.4%GBX 435+22.1%-2.1%£32.17B£11.07B29.9725,408BXPBeximco PharmaceuticalsN/AGBX 47.11-0.8%N/A+71.2%£32.11B£7.08T5.055,500HIKHikma Pharmaceuticals4.1022 of 5 starsGBX 1,793.30+0.2%GBX 2,627.50+46.5%-9.1%£4.97B£3.74B17.609,100News CoverageInsider TradeHCMHUTCHMEDN/AGBX 243+3.8%N/A-11.8%£2.64B£771.01M-62.021,760News CoverageGap UpINDVIndivior2.4889 of 5 starsGBX 1,238+1.6%GBX 1,650+33.3%+34.8%£1.93B£1.40B-1,026.481,000Gap UpHigh Trading VolumeAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 7.50-10.7%N/A+82.8%£368.63M£72.18M-7.23612News CoverageGap UpAPHAlliance Pharma2.1061 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 262.88-0.4%N/A-5.1%£180.23M£84.90M4.90220News Coverage Related Companies and Tools Related Companies Hellenic Dynamics Alternatives Haleon Alternatives Beximco Pharmaceuticals Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Animalcare Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:N4P) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access